Lindbrook Capital, LLC Bei Gene, Ltd. Transaction History

Lindbrook Capital, LLC

  • $1.18 Billion
  • Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 207 shares of BGNE stock, worth $38,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207
Previous 207 -0.0%
Holding current value
$38,166
Previous $29,000 58.62%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 21, 2022
SELL
$146.52 - $269.56 $10,989 - $20,217
-75 Reduced 26.6%
207 $39,000
Q4 2021

Jan 18, 2022
SELL
$248.56 - $389.34 $7,953 - $12,458
-32 Reduced 10.19%
282 $76,000
Q3 2021

Nov 05, 2021
BUY
$249.6 - $403.14 $2,745 - $4,434
11 Added 3.63%
314 $114,000
Q2 2021

Jul 27, 2021
BUY
$292.75 - $367.01 $878 - $1,101
3 Added 1.0%
303 $104,000
Q4 2020

Jan 27, 2021
SELL
$221.31 - $316.61 $4,426 - $6,332
-20 Reduced 6.25%
300 $78,000
Q3 2020

Nov 03, 2020
BUY
$189.18 - $286.44 $10,594 - $16,040
56 Added 21.21%
320 $92,000
Q2 2020

Jul 27, 2020
BUY
$123.9 - $195.41 $27,505 - $43,381
222 Added 528.57%
264 $50,000
Q1 2020

Apr 22, 2020
BUY
$121.84 - $173.19 $5,117 - $7,273
42 New
42 $5,000
Q4 2019

Jan 27, 2020
SELL
$115.78 - $208.34 $6,367 - $11,458
-55 Closed
0 $0
Q2 2019

Jul 24, 2019
BUY
$113.99 - $146.86 $911 - $1,174
8 Added 17.02%
55 $6,000
Q1 2019

Apr 23, 2019
BUY
$122.82 - $151.83 $5,772 - $7,136
47 New
47 $6,000

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.1B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email